Published in Aging (Albany NY) on February 22, 2017
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet (2009) 5.01
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13
Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet (2012) 2.86
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res (2003) 1.94
The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem (2008) 1.36
Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis (2002) 1.32
Association of genetic variation in mitotic kinases with breast cancer risk. Breast Cancer Res Treat (2009) 1.02
Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem (2000) 1.02
Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci (2003) 1.01
Associations of PI3KR1 and mTOR polymorphisms with esophageal squamous cell carcinoma risk and gene-environment interactions in Eastern Chinese populations. Sci Rep (2015) 1.00
Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast cancer cells. FEBS Lett (2010) 0.99
Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications. Am J Physiol Endocrinol Metab (2008) 0.98
Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle. Int J Oncol (2013) 0.91
Potential effect on cellular response to cadmium of a single-nucleotide A --> G polymorphism in the promoter of the human gene for metallothionein IIA. Hum Genet (2006) 0.89
Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer (2013) 0.89
Gains, losses and changes of function after gene duplication: study of the metallothionein family. PLoS One (2011) 0.88
Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection. J Transl Med (2013) 0.88
Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett (2008) 0.87
Epidemiology, Incidence and Mortality of Breast Cancer in Asia. Asian Pac J Cancer Prev (2016) 0.86
Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med (Maywood) (2006) 0.85
Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population. J Cell Mol Med (2016) 0.84
Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population. Med Oncol (2014) 0.82
Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer. Clin Exp Med (2012) 0.81
Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population. Cancer Genet (2012) 0.80
Metallothionein 2A core promoter region genetic polymorphism and its impact on the risk, tumor behavior, and recurrences of sinonasal inverted papilloma (Schneiderian papilloma). Tumour Biol (2015) 0.79
Impact of metallothionein gene polymorphisms on the risk of lung cancer in a Japanese population. Mol Carcinog (2014) 0.79
Metallothionein 2 regulates endothelial cell migration through transcriptional regulation of vegfc expression. Angiogenesis (2015) 0.78
Metallothionein 2A expression and its relation to different clinical stages and grades of breast cancer in Egyptian patients. Gene (2015) 0.78
Bone mineral density and polymorphisms in metallothionein 1A and 2A in a Chinese population exposed to cadmium. Sci Total Environ (2012) 0.77
Clinicopathological significance of altered metallothionein 2A expression in gastric cancer according to Lauren's classification. Chin Med J (Engl) (2013) 0.77
Distinct role of the Fas rs1800682 and FasL rs763110 polymorphisms in determining the risk of breast cancer among Han Chinese females. Drug Des Devel Ther (2016) 0.77
Evaluation of apoptosis, proliferation intensity and metallothionein (MT) expression in comparison with selected clinicopathological variables in primary adenocarcinomas of the large intestine. Folia Morphol (Warsz) (2004) 0.77
Single-nucleotide polymorphisms in PSCA and the risk of breast cancer in a Chinese population. Oncotarget (2016) 0.81
Genetic association of deleted in colorectal carcinoma variants with breast cancer risk: A case-control study. Oncotarget (2016) 0.78
Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy. J Cancer (2017) 0.78
Polymorphisms in TIM-3 and breast cancer susceptibility in Chinese women: A case-control study. Oncotarget (2016) 0.77
MiR-146a and miR-196a-2 polymorphisms are associated with hepatitis virus-related hepatocellular cancer risk: a meta-analysis. Aging (Albany NY) (2017) 0.75
Association of transcription factor 7-like 2 gene polymorphisms with breast cancer risk in northwest Chinese women. Oncotarget (2016) 0.75
Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk. Oncotarget (2016) 0.75
FEN1 gene variants confer reduced risk of breast cancer in chinese women: A case-control study. Oncotarget (2016) 0.75
TLR1 polymorphism rs4833095 as a risk factor for IgA nephropathy in a Chinese Han population: A case-control study. Oncotarget (2016) 0.75
Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers. Oncotarget (2017) 0.75
Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers. Oncotarget (2017) 0.75